Glimisave M3 Forte Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 3 mg and Metformin 1000 mg, designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glycemic control. This dual-action formulation addresses both insulin secretion defects and insulin resistance, making it effective for patients inadequately controlled on diet and exercise alone. The prolonged-release (PR) formulation ensures a steady release of active ingredients, promoting better tolerance and adherence by minimizing gastrointestinal side effects commonly associated with metformin. Glimisave M3 Forte is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, particularly when monotherapy with either agent is insufficient. Dosage should be individualized based on patient response and tolerability, with regular monitoring of blood glucose and renal function recommended. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoglycemia. This combination therapy offers a convenient and effective option for optimizing glycemic management in type 2 diabetes.